Efficacy of Atropine 0.01% for the Treatment of Childhood Myopia
PURPOSE: To evaluate the efficacy and safety of atropine 0.01% in slowing myopia progression in European paediatric patients.
METHODS: Retrospective, medical records review study
RESULTS: Medical records of 52 treated and 50 control subjects were analysed. In the atropine group, the mean rate of myopia progression after 12 months of treatment (-0.54 ± 0.61 D) was significantly slower compared with the baseline progression (-1.20 ± 0.64 D; p < 0.0001) and to the progression in the control group (-1.09 ± 0.64; p < 0.0001). The responders patients were 41/52 (79%), whereas 11/52 patients (21%) showed a progression > 0.50 D despite treatment. The only adverse event was temporary photophobia in five patients (9.6%), severe adverse events were not reported, and none of the patients discontinued the treatment.
CONCLUSION: Low-dose atropine significantly slowed the rate of myopia progression in European paediatric patients with a favourable safety profile.
Reference: Efficacy of Atropine 0.01% for the Treatment of Childhood Myopia in European Patients. Acta Ophthalmol 2019 Jun 13;[EPub Ahead of Print], M Sacchi, M Serafino, E Villani, E Tagliabue, S Luccarelli, F Bonsignore, P Nucci
TAKE HOME MESSAGE:
This study retrospectively assessed the efficacy and safety of atropine 0.01% in slowing the progression of myopia among children.
As compared with the control group, the rate of myopia progression was significantly slower in the treatment group after 12 months of treatment.
Low-dose atropine appears to be beneficial in slowing myopia progression.